A Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With ANCA-Associated Vasculitis
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
The aim of this trial is to optimize the treatment to induce remission for patients with
non-life-threatening anti-neutrophil cytoplasmic antibody vasculitis (AAV). The intent is to
reduce the toxicity of induction therapy by reducing the overall exposure to or eliminating
entirely the use of systemic corticosteroids during the induction period with an inhibitor of
the complement C5a receptor plus cyclophosphamide or rituximab.